We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

Orexin Receptors

Orexin receptor antagonists block orexin receptors 1 and 2 (OX1, OX2), which respond to orexin neuropeptides. Orexin A and orexin B were described in 1998 as hypothalamic peptides that act on these two G protein-coupled receptors. In 1999 a mutation in the orexin receptor 2 gene was found to cause canine narcolepsy. Mice lacking orexin showed a narcolepsy-like phenotype in the same year, linking the system to sleep and wakefulness. OX1 is also studied in reward, addiction and stress, and OX2 mainly in arousal. SB 334867, SB-408124 and GSK1059865 are OX1-selective antagonists, and MK-3697 targets OX2. Almorexant, TCS 1102 and nemorexant are dual antagonists that block both orexin receptors.

2 Items

  • Alixorexton
    Cat. No.
    A62708
    CAS No.
    2648347-56-0

    Alixorexton

    Synonyms: ALKS 2680

    Alixorexton is a selective OX2R activator that effectively crosses the blood-brain barrier, functioning as a wake-promoting agent. This compound is primarily utilized in research related to sleep disorders, including narcolepsy and idiopathic hypersomnia, making it a valuable tool for investigating the mechanisms of sleep regulation and potential therapeutic interventions.

    In stock View Details
    1 mg
    $360.00
    5 mg
    $945.00
    All 6 sizes
  • Efizonerimod alfa
    Cat. No.
    A62727
    CAS No.
    1635395-27-5

    Efizonerimod alfa

    Synonyms: MEDI-6383

    Efizonerimod alfa is a potent monoclonal antibody that functions as an OX40 activator. This reagent enhances T-cell activation and proliferation, making it particularly relevant for cancer research and immunotherapy studies. Its ability to modulate immune responses positions it as a valuable tool for investigating therapeutic strategies in oncology.

    In stock View Details
    1 mg
    $400.00
    5 mg
    $1,065.00
    All 3 sizes

2 Items

Added to your cart

View Cart Checkout

    Loading...